Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Canagliflozin on liver steatosis in obese non-diabetic patients with non-alcoholic fatty liver disease
TCTR20190118008Phase 3Completed
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of canagliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, sponsored by Ratchadaphiseksomphot Endowment Fund. Started Jul 2019; status: completed.
02
Drugs
canagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)obesity
Beyond the preview
Go deeper on TCTR20190118008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190118008.